Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Head and Neck Cancer Pipeline Report 2017 -

Research and Markets
Posted on: 21 Feb 18

The "Head and Neck Cancer: Pipeline" report has been added to's offering.

In-depth analysis of key pipeline products for head and neck cancer in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK), including new clinical data and a comparative evaluation of clinical and commercial drug attributes to determine competitiveness in the marketplace.


Gilotrif has had a troubled development thus far and is not expected to gain regulatory approval in the US, Japan, or five major EU markets. However, the drug experiences limited off-label use due to its category 2B recommendation from the National Comprehensive Cancer Network, and is under Phase III development for use in emerging markets.

Imfinzi is expected to be the third immunotherapy approved for the treatment of head and neck cancer, and will face significant competition from established immunotherapies. In particular, Opdivo and Imfinzi are both under late-phase development for first-line use in combination with CTLA-4 inhibitors Yervoy and tremelimumab, respectively. Nonetheless, Imfinzi is still likely to experience modest uptake due to the lack of treatment options currently approved for head and neck cancer.

Merck KGaA and Pfizer will attempt to minimize direct competition with other immunotherapies by positioning Bavencio for first-line and maintenance use in combination with chemoradiotherapy in locally advanced patients. While maintenance therapy in advanced head and neck cancer is not well established, the lack of competition could allow the drug to gain modest uptake.

Key Topics Covered:

  1. Executive Summary
  2. Clinical Pipeline Overview
  3. Recently Discontinued Drugs
  4. Comparator Therapy
  5. Product profile (late stage): Gilotrif
  6. Product profile (late stage): Javlor
  7. Product profile (late stage): Keytruda
  8. Product profile (late stage): Multikine
  9. Product profile (late stage): Opdivo
  10. Product profile (late stage): Reolysin
  11. Product profile (late stage): durvalumab

For more information about this report visit

View source version on

Business Wire

Last updated on: 21/02/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.